Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI contrast agent may improve artery blockage detection in legs

NCT ID NCT00707876

Diagnosis Sponsor: AMAG Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two MRI methods for finding narrowed or blocked arteries in the pelvis and legs of 119 people with peripheral arterial disease (PAD). One method uses a special dye called ferumoxytol to make blood vessels stand out, while the other relies on natural blood flow. Both were compared to a standard X-ray technique. The goal was to see which MRI approach is more accurate and safer for diagnosing PAD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

119 people

The number who actually took part.

Started

Sep 2008

Finished

Aug 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects with symptoms of PAD * Scheduled for DSA Exclusion Criteria: * Critical leg ischemia manifested by ulcers, gangrene or leg amputation * Laboratory evidence of iron overload, liver disease, pregnancy * History of allergy to or recent exposure to radiocontrast, gadolinium chelates, or intravenous iron therapy * Clinical concerns about co-morbidities, subject suitability

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peripheral arterial disease(PAD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

peripheral arterial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Peripheral arterial disease(PAD)

Contacts and locations

Locations

  • Study site

    Lexington, Massachusetts, 02421, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.